CymaBay Therapeutics
Présence
CymaBay Therapeutics fait partie des...
CymaBay Therapeutics est une société cotée sous le symbole boursier CBAY (US).
Acquisition, funding and merger involving CymaBay Therapeutics.
- Gilead Sciences has announced the acquisition of CymaBay Therapeutics (publié le 15 février 2024).
Dirigeants
Voir l'organigramme avec ses 16 principaux dirigeants
Biographies les plus recherchées chez CymaBay Therapeutics
- Sujal Shah, Director, President and Chief Executive Officer
- Robert Wills, Executive Chairman of the Board
- Caroline Loewy, Director
Changements de dirigeants chez CymaBay Therapeutics
- Lewis Stuart, Chief Commercial Officer, quittera l'entreprise le 31 déc. 2023 (publié le 22 décembre 2023).
- Ben Kozub qui est Vice President, Liver Franchise, sera promu Chief Commercial Officer le 31 déc. 2023 (publié le 22 décembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez CymaBay Therapeutics.
Pharmacie
CymaBay Therapeutics a 1 861 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par CymaBay Therapeutics
- CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
- CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
- CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
- Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
- CymaBay Therapeutics to Participate in Upcoming Investment Conferences
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de CymaBay Therapeutics
- CymaBay Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- CymaBay Therapeutics sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Sujal Shah 
Appelez CymaBay Therapeutics au +1 510...
